tbuckley/cabot-search huggingface dataset:
BOOK REVIEWS
Authors: G. FALKSON
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article BOOK REVIEWS Get access Early Detection and Treatment of Liver Cancer . Kunio Okuda , Takayoshi Tobe , Tomoyuki Kitagawa , eds. Tokyo : Jpn. Sci. Soc. Press ; London : Taylor & Francis , 1991 . 228 pp., illus. $99 GEOFFREY FALKSON, M.D. GEOFFREY FALKSON, M.D. Department of Medical Oncology, University of PretoriaPrivate Bag X 169 Pretoria 0001 Republic of South Africa Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 18, 16 September 1992, Page 1441, https://doi.org/10.1093/jnci/84.18.1441 Published: 16 September 1992
Antibodies to tumor necrosis factor-? inhibit cell replication caused by the peroxisome proliferator WY-14,643 . Dept. of Pharmacology and Curriculum in Toxicology1, Dept. of Environmental Sciences and Engineering3, University of North Carolina, Chapel Hill, NC 27599 and Immunology and Neurobiology Section2, NIEHS, RTP, NC 27709
Journal: Hepatology (1995)
BOOK REVIEWS
Authors: N. POTISCHMAN
Journal: JNCI Journal of the National Cancer Institute (1989)

BOOK REVIEWS Carcinogenesis and Dietary Fat. S. Abraham, ed. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1989, 492 pp. $125. NANCY POTISCHMAN NANCY POTISCHMAN Environmental Epidemiology Branch, National Cancer InstituteExecutive Plaza North, Rm. 443, Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 23, 6 December 1989, Pages 1834–1835, https://doi.org/10.1093/jnci/81.23.1834 Published: 06 December 1989
Reply: Does reference value of “Normal Liver Stiffness” using fibroscan have a regional variation?
Authors: Abhijit Chowdhury, Kausik Das
Journal: Hepatology (2012)

We thank Kumar et al. for their interest in our article.1 We appreciate their concern and would like to reiterate that the strength of our data and its implication in liver stiffness measurements (LSMs) is the result of the inclusion of a statistically representative sample of healthy people drawn from a systemically maintained community health database, thus negating the "selection bias" inherent in any sample drawn from "free health/medical check-up" and functional dyspeptics.2, 3 We excluded the effect of social consumption of alcohol, drugs, viral hepatitis, and even ultrasound-diagnosed nonalcoholic fatty liver disease (NAFLD) in our healthy sample. Liver biopsy could not be done in these asymptomatic healthy subjects because of ethical reasons. Second, although we used World Health Organization–proposed categories for body mass index (BMI), distribution pattern of LSM remained similar (i.e., "U-shaped"), when Asian-specific categories were applied (i.e., LSM values were 6.03 ± 1.77, 5.62 ± 1.64, 5.37 ± 1.51, and 5.96 ± 1.25 kPa, respectively, in BMI categories <18.5 [n = 92], 18.5-23.0 [n = 214], 23.0-27.5 [n = 98], and >27.5 kg/m2 [n = 14], respectively). Third, the failure rate of transient elastography (4.35%) in healthy subjects was consistent with that reported in the literature.2, 3 Fourth, in our study, LSM increased in obese and underweight vis-à-vis those with healthy BMI, because, unlike other studies, our healthy cohort had a wide spectrum of BMI. We had earlier shown that nonobese people in the developing world have significant liver disease, often related to NAFLD.4 Given the intricate relationship between emerging liver diseases, lifestyle, and nutrition, it may be appropriate to view our data in a perspective for the assessment of liver diseases in the developing countries, where these determinants prevail. Finally, the 95th percentile value of LSM in the nonobese healthy men of the French cohort was 8.0 kPa.2 Efficacy of 8 kPa as the cutoff was validated in a recent community study.5 For the purpose of using LSM in the community, we need to have a trigger point that is scientifically justified and, at the same time, minimize unnecessary healthcare resource usage. We think the cut-off value of 8.5 kPa derived from our cohort is acceptable, when community application of LSM is an issue. We look forward to further studies on the validation of our data in the region. Abhijit Chowdhury M.D., D.N.B., D.M.*, Kausik Das M.D., D.M.*, * Department of Hepatology, School of Digestive and Liver Diseases, IPGME&R, Kolkata, India.
Comparison of ammonium alum and tannic acid as barium enema additives
Authors: G. M. Wyatt
Journal: JAMA (1966)

This is a preliminary report on ammonium alum as a substitute for the tannic acid formerly used in barium sulfate enemas to promote colon contraction and barium coating of the colon mucosa. The "mucosal pattern" thus produced on postevacuation films is useful in tumor diagnosis because a tumor larger than the contracted lumen produces a bulge or distortion of this pattern. Experimental and clinical studies indicate that alum is equal to tannic acid in every respect except that it does not maintain colon contraction quite as long. Either additive is far better than none. Alum was not toxic in the amounts found effective.
CONTROL OF DRUGS AND MEDICAL SUPPLIES
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SURGERY IN EXOPHTHALMIC GOITER.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
USAN Council. List no. 122. New names
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging
Authors: T. R. Chaudhuri, Z. Cao, S. Ponnazhagan, A. Stargel, P. L. Simhadri, T. Zhou, A. F. Lobuglio, D. J. Buchsbaum, K. R. Zinn
Journal: Journal of Clinical Oncology (2004)

742 Background: TRA-8, a mouse anti-human DR5 monoclonal antibody induces apoptosis in TRAIL-sensitive tumor cells. However no non-invasive method is available to monitor the treatment effects on disseminated cancer. We report a non-invasive and sensitive BI technology to determine the efficacy of combined treatment of TRA-8 and Adriamycin on disseminated breast cancer in animal model. Methods: Human breast cancer cell line 2LMP, a subclone of MDA-MB-231, was transfected with adeno associated virus encoding luciferase (AAV-luc). A stable luciferase-positive cell line was established by screening. Two groups (5/group) of athymic female nude mice were used. Four sites (liver, spleen, chest cavity and peritoneum) of each mouse were injected with luciferase-positive 2LMP cells (0.25x106/site). After 7 days, BI revealed disseminated tumor sites; one group of mice was injected i.v. with 150 μg TRA-8 and 6 mg/kg Adriamycin, and the 2nd group of mice did not receive any treatment. All treatments were given 2X/wk for 3 wks. Mice were imaged over time with an IVIS-100 Xenogen imaging system and tumor mass was estimated from ventral, dorsal, left and right lateral views by measuring light transmitted from the luciferase positive tumors. Results: All untreated mice died by day 21 with 4–6 fold increases in bioluminescence and extensive metastasis, including bone. Treated mice had a dramatic decrease in bioluminescence to 15–20% of day 7 values that persisted for 45 days and then began a progressive regrowth of tumor (increasing bioluminescence) in multiple sites. Dissemination of breast cancer was detected by BI and confirmed by dissection. In all untreated mice, numerous tumor nodules were detected in lungs, heart, pleural space, bones including ribs and spine, diaphragm, esophagus and pericardium, liver, spleen, stomach, kidneys, ovaries, uterus, and peritoneal membrane. Conclusions: BI demonstrated high sensitivity for non-invasive detection and treatment monitoring of disseminated breast tumors in mice. Combination therapy with TRA-8 and Adriamycin was highly effective in the regression of disseminated breast cancer in this animal model. No significant financial relationships to disclose.
Serum Immunoglobulin Free Light Chain in Primary Amyloidosis: Prognostic Value and Correlations with Clinical Features
Authors: Shaji Kumar, Angela Dispenzieri, Raynell Clark, Dirk Larson, Colin Colby, Steve Zeldenrust, Martha Lacy, Suzzane Hayman, Francis Buadi, Nelson Leung, Marina Ramirez-Alvarado, Robert Kyle, Jerry Katzmann, S. Vincent Rajkumar, Morie Gertz
Journal: Blood (2008)
News in brief
Journal: Nature Reviews Drug Discovery (2011)

First priority review voucher wastedNovartis redeemed its priority review voucher earlier this year to secure a speedy assessment of canakinumab in gouty arthritis, but the FDA nevertheless recently ruled against approval.The lowdown: In 2007, the US government created priority review vouchers to encourage companies to work on drugs for neglected diseases.Through this programme, firms that successfully developed new therapeutics addressing these unmet medical needs would be rewarded with a single-use voucher guaranteeing a priority review for a subsequent drug submission of the sponsor's choice.David Ridley and his colleagues at Duke University, Durham, North Carolina, USA, who first proposed the scheme in 2006 (Health Aff. 25, 313-324; 2006), estimated that the faster review time and potentially speedier move towards commercialization could be worth as much as US$320 million.The first, and as yet only, voucher was granted to Novartis in 2009 when the US Food and Drug Administration (FDA) approved the artemether plus lumefantrine combination therapy for the treatment of malaria.Novartis used the voucher to secure a 6-month review for canakinumab in gouty arthritis, but the agency rejected the dossier in August and asked for more data to assess the antibody's profile in refractory patients.Although the decision highlights the uncertainty surrounding the valuation of the vouchers, Ridley argues that the experience demonstrates that the FDA will honour the coupon.He adds that it was a bit of a surprise that Novartis received the voucher in the first place because the firm's antimalarial had been in use since 2001 outside the United States."In the future, we'd like to reward products that would not have otherwise been developed," says Ridley.Companies developing tuberculosis drugs that are currently in Phase II trials could be the next recipients of the voucher, he adds.An effort is also underway to sweeten the terms of the voucher.If the US government approves the Creating Hope Act, vouchers would become easier to redeem and fully transferable (they can currently only be sold once).
Abrogation of TLR4 and CD14 Expression and Signaling in Human Adrenocortical Tumors
Authors: Waldemar Kanczkowski, Piotr Tymoszuk, Monika Ehrhart-Bornstein, Manfred P. Wirth, Kai Zacharowski, Stefan R. Bornstein
Journal: Endocrine Reviews (2010)

Adrenocortical carcinoma (ACC) is a rare tumor with poor prognosis. The expression of innate immunity receptor Toll-like receptor (TLR)-4 was recently reported in various human tumors, and TLR4 was shown to regulate tumor immune escape processes, proliferation, and resistance to chemotherapeutical agents. The aim of this study was to investigate TLR4 expression, signaling, and function in the process of tumorigenesis in the human adrenal cortex. Real-time PCR analysis of human ACC (n = 8), adenoma (n = 8), and ACC cell lines (SW13, NCI-H295R, and HAC15) revealed a significant down-regulation of TLR4, MD2, and CD14 mRNA compared with normal human adrenal cortex and adrenocortical cells in primary culture. Furthermore, immunohistochemistry revealed an abrogation of TLR4 and CD14 expression in ACC but not adenoma tissues. Western blot analysis of MAPK, AKT, activator protein-1, and nuclear factor-κB signaling revealed that the ACC cell lines are unresponsive to lipopolysaccharide action. Restoration of TLR4 signaling by stable transfection of TLR4-CD14 plasmid into NCI-H295R cells sensitized them to lipopolysaccharide incubation as shown by nuclear factor-κB activation and decreased cell viability and induced apoptosis in these cells. Our results demonstrate a significant reduction in the expression of TLR4 and CD14 and an inactivation of TLR4 signaling in ACCs. Furthermore, our data show that reintroduction of TLR4 expression in ACCs may provide a novel therapeutic strategy for adrenal cancer.
Figure Upside Down
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LETTER FROM NEW YORK.
Authors: None P. B. P.
Journal: JAMA (1889)

(FROM OUR REGULAR CORRESPONDENT.) The Influence of Carlsbad Water in Uric Acid Excretion—Auto-Infection from Gastro-Intestinal Fermentation—The Section in Practice of Medicine of the New York Academy Reëlects its Chairman. At the last meeting of the Section in Practice of Medicine of New York Academy, Dr. Schuman Le Clercq, of Carlsbad, read a paper on the<i>Influence of Carlsbad Water on Uric Acid Excretion</i>, in which he gave the results of a series of careful experiments on his own person. Dr. F. H. Otis added his personal experience and observation in the treatment of obesity and hepatic derangement. The Chairman, Dr. R. C. M. Page, said that individuals who had too much fat and those who had an excess of uric acid would derive benefit from the treatment; but for those suffering from Bright's disease or pulmonary trouble, or from any grave depression of vitality, it was only attended with evil.
Correction
Journal: BMJ (1956)

isoniazid at home and even, if he is well enough, at work.It is not at-all unusual to find cell count and protein level in the C.S.F.still high at three months.From the prognostic point of view, far the most important element to be determined is the sugar content.Treatment should never be stopped before this is consistently above 50 mg.per 100 ml.It may well not be achieved for six months or more, but even then, as already indicated, it would be wise to continue treatment for at least a full year.
Amphetamine Cardiomyopathy
Authors: PERRY R. AYRES
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 January 1983Amphetamine CardiomyopathyPERRY R. AYRES, M.D.PERRY R. AYRES, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-1-110_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Reports by Call and associates (1) and Croft and colleagues (2) on cardiomyopathy from intravenous injection of amphetamine and propylhexedrine called to my mind a physician I treated 20 years ago. The case records are not available, but the details are etched in my memory.A 38-year-old small-town family physician of Irish descent was well-nourished and not alcoholic. The patient had had excellent health until he abruptly developed severe dyspnea and orthopnea without peripheral edema, chest pain, or fever. The physician's self-diagnosis, based on a chest roentgenogram made in his community hospital, was acute pericarditis with effusion....References1. CALLHARTNECKDICKINSONHARTMANBARTEL TJWCA. Acute cardiomyopathy secondary to intravenous amphetamine abuse. Ann Intern Med. 1982;97:559-60. LinkGoogle Scholar2. CROFTFIRTHHILLIS CBL. Propylhexedrine-induced left ventricular dysfunction. Ann Intern Med. 1982;97:560-1. LinkGoogle Scholar3. WILFORD B. The drug abusing physician. In: Drug Abuse: A Guide for the Primary Care Physician. Chicago: American Medical Association; 1981: 285-97. Google Scholar4. AYRES P. The physician drug addict. In: CALLAN JP, ed. The Physician. New York: Appleton Century-Croft; 1983. (In press). Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: PERRY R. AYRES, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHeart Failure in Vulnerable Populations: The Emerging Evidence of Methamphetamine-Associated CardiomyopathyMethamphetamine use and heart failure: Prevalence, risk factors, and predictorsExposure to Amphetamines Leads to Development of Amphetamine Type Stimulants Associated Cardiomyopathy (ATSAC)Cardiac Toxins and Drug‐Induced Heart DiseaseCardiomyopathy Due to Ingestion of AdderallMethamphetamine and cardiovascular pathology: a review of the evidenceCrystal Methamphetamine‐Associated Cardiomyopathy: Tip of the Iceberg?Cardiovascular effects of adolescent drug abuse‘Designer Drugs’ 1 January 1983Volume 98, Issue 1Page: 110-110KeywordsAmphetaminesCardiomyopathiesDyspneaEdemaFeversIntravenous injectionsIschemiaMemorySelf diagnosisThorax ePublished: 1 December 2008 Issue Published: 1 January 1983 PDF downloadLoading ...
Malignant Melanoma
Authors: Peter I. Reed, Howard F. Raskin, Phillip W. Graff
Journal: JAMA (1963)

<h3>To the Editor:</h3> —We appreciate Dr. Pack's review of our case and his comments. However, the purpose of our report was to record the description of the gastroscopic appearance of a malignant melanoma involving the stomach, in which the diagnosis was confirmed by exfoliative cytology and gastroscopic biopsy. We are aware that metastatic malignant melanoma is found to involve the stomach at autopsy, but it is most unusual, in our clinical experience, for the diagnosis to be first suggested by the diagnostic sequence as outlined. We regret that the conclusions of our report were misinterpreted.
Patient Education
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antiarrhythmic Agents: The Modulated Receptor Mechanism of Action of Sodium and Calcium Channel-Blocking Drugs
Authors: L. Hondeghem
Journal: The Annual Review of Pharmacology and Toxicology (1984)

Due to the massive data sets available for drug candidates, modern drug discovery has advanced to the big data era. Central to this shift is the development of artificial intelligence approaches to implementing innovative modeling based on the dynamic, ...Read More